KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 27 2024 - 6:30AM
Business Wire
– Patient perspectives revealed frequent
treatment delays, suboptimal clinical outcomes and substantial
anxiety associated with injectable on-demand treatments, including
those who received long-term prophylaxis -
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today announced that it presented real-world data from US patient
surveys that assessed the experience of HAE patients using
injectable on-demand treatments at the 2024 American Academy of
Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took
place in Washington, DC.
The following presentations occurred at AAAAI 2024:
- Characteristics of Hereditary Angioedema Attacks Among
Long-Term Prophylaxis Users: Bob Geng, Allergy and Immunology,
University of California, San Diego, California, United States
(Poster Presentation)
- Among HAE patients who had treated a recent attack, the
location and duration of the most recent attacks were similar
between long-term prophylaxis (LTP) and on-demand only users
- Earlier on-demand treatment was associated with a shorter
attack duration, regardless of LTP use
- Delayed On-demand Treatment of Hereditary Angioedema
Attacks: Patient Perceptions and Associated Barriers: Sandra
Christiansen, University of California San Diego, La Jolla, CA,
United States (Poster Presentation)
- Despite their perception of treating attacks “early”, many
patients did not meet guideline recommendations for prompt
on-demand treatment after recognition of an HAE attack
- The most common barriers to earlier treatment were uncertainty
if attack was real, thinking the attack would be mild, and wanting
to save treatment for a severe attack
- Anxiety Associated with On-Demand Treatment for Hereditary
Angioedema (HAE) Attacks: James Wedner, Washington University
School of Medicine, St Louis, MO, United States (Poster
Presentation)
- Both adults and adolescents with HAE reported moderate to
extreme anxiety when anticipating use of parenteral on-demand
treatment, irrespective of use of on-demand only or on-demand plus
LTP
- The results of this study highlighted the association between
delayed treatment and treatment-related anxiety, with a higher
proportion of patients who delayed treatment experiencing moderate
to extreme anxiety
- Anxiety Associated with Refilling On-demand Therapy for HAE
Attacks Contributes to Treatment Delay and Non-Treatment:
Autumn Burnette, Division of Allergy and Immunology, Howard
University Hospital, Washington, DC, United States (Poster
Presentation)
- Anxiety associated with not being able to refill on-demand
treatment quickly impacted treatment decisions, which contributed
to treatment delay or resulted in non-treatment of HAE attacks
- One-third of patients using icatibant did not treat or delayed
treatment due to anxiety about refills
- Characterizing the Negative Impact of Delayed On-Demand
Treatment of HAE Attacks: Princess Ogbogu, Division of
Pediatric Allergy, Immunology, and Rheumatology, University
Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio,
United States (Poster Presentation)
- People living with HAE understood the importance of treating
HAE attacks early and recognized that earlier treatment translates
to quicker recovery and resolution
- Delayed on-demand treatment (> 1 hour) lengthened the time
to “feeling in control” of an attack and the time to feeling fully
recovered
- The Impact of On-demand Treatment on Quality of Life of
People with HAE: Paula Busse, Department of Medicine, Division
of Clinical Immunology, Mount Sinai, New York, United States
(Poster Presentation)
- People with HAE needed to make adjustments to their daily lives
including avoiding situations where their injectable on-demand
treatment may be discovered by others
- Embarrassment associated with carrying on-demand treatment was
among the reasons HAE patients delayed administration of on-demand
treatment
- Characterizing the Perspective of Patients With HAE on
Prophylactic Treatment: Stephen Betschel, Division of Allergy
and Immunology, Department of Medicine, St. Michael’s Hospital,
University of Toronto, Toronto, Ontario, Canada (Poster
Presentation)
- Only 35% of LTP patients always carried on-demand treatment
when away from home, while 43% of prophylaxis patients cited
avoiding potential triggers as a reason for not carrying on-demand
treatment at all times
- Nearly half of patients on LTP patients experienced moderate to
extreme levels of anxiety when anticipating on-demand treatment
administration
- Treatment Patterns of Patients Requiring Redosing of an
On-demand Treatment After the Return of an HAE Attack:
Constance Katelaris, Department of Medicine, Campbelltown Hospital
and Western Sydney University, Sydney, NSW, Australia (Poster
Presentation)
- Almost one third of people with HAE experienced the return of
an HAE attack requiring ≥1 additional dose of on-demand
treatment
- HAE attacks treated within 1 hour returned less frequently
compared with attacks treated after ≥1 hour
“The results of these surveys clearly conveyed the challenges
faced by patients trying to manage their HAE attacks with
injectable on-demand treatments. The resulting non-compliance with
treatment guidelines may lead to poor clinical outcomes, even among
patients receiving LTP,” said Andrew Crockett, Chief Executive
Officer of KalVista. “We believe the efficacy and safety data from
our phase 3 trial for sebetralstat show a potential path forward to
address these persisting unmet needs.”
Links to all posters and presentations can be found on the
KalVista website under “Publications”.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista disclosed positive phase 3 data
for the KONFIDENT trial for its oral, on-demand therapy
sebetralstat in February 2024. The Company anticipates submitting a
new drug application to the U.S. FDA for sebetralstat in the first
half of 2024 and expects to file for approval in Europe and Japan
later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor
program represents a new generation of therapies that may further
improve the treatment for people living with HAE and other
diseases.
For more information about KalVista, please visit
www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and its results, our ability to commence clinical
studies or complete ongoing clinical studies, including the
KONFIDENT-S trial, and to obtain regulatory approvals for
sebetralstat and other candidates in development, the success of
any efforts to commercialize sebetralstat, the ability of
sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2023, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227931159/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2024 to May 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From May 2023 to May 2024